Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Plus Therapeutics Inc PSTV

Healthcare Biotechnology
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma... see more

Recent & Breaking News (NDAQ:PSTV)

Plus Therapeutics Completes Enrollment of Cohort 1 ReSPECT-LM Phase 1/2a Trial

GlobeNewswire June 16, 2022

Plus Therapeutics Reports Positive Clinical Outcomes from ReSPECT-GBM Trial at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting

GlobeNewswire June 13, 2022

Plus Therapeutics to Present Virtually at the 2022 HC Wainwright Global Investment Conference

GlobeNewswire May 18, 2022

Plus Therapeutics to Present at the 2022 Q2 Investor Summit

GlobeNewswire April 26, 2022

Plus Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

GlobeNewswire April 21, 2022

Plus Therapeutics Announces Oral Presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting

GlobeNewswire April 19, 2022

Plus Therapeutics to Announce First Quarter 2022 Financial Results and Host Conference Call on April 21, 2022

GlobeNewswire April 14, 2022

Plus Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire April 8, 2022

Plus Therapeutics and Medidata Announce Expanded Clinical Trial Partnership

GlobeNewswire April 5, 2022

Plus Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

GlobeNewswire March 23, 2022

Plus Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of 186RNL Radiotherapeutic for Leptomeningeal Metastases

GlobeNewswire March 22, 2022

Plus Therapeutics Announces Upcoming Participation at the 2022 SNMMI Therapeutics Conference

GlobeNewswire March 3, 2022

Plus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

GlobeNewswire February 24, 2022

Plus Therapeutics Partners with Medidata to Apply Innovative Synthetic Control ArmⓇ Solution to Accelerate Brain Cancer Clinical Trial

GlobeNewswire February 22, 2022

Plus Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 24, 2022

GlobeNewswire February 18, 2022

Plus Therapeutics to Present at BIO CEO & Investor Conference

GlobeNewswire February 7, 2022

Plus Therapeutics to Participate in Upcoming January Conferences

GlobeNewswire January 7, 2022

Plus Therapeutics Significantly Expands Investigational Oncology Drug Pipeline

GlobeNewswire January 6, 2022

Plus Therapeutics Announces Two Significant Milestones Toward cGMP Manufacture of its Lead Investigational Radiotherapeutic

GlobeNewswire January 4, 2022

Plus Therapeutics to Present at MedInvest Oncology Investor Conference

GlobeNewswire December 2, 2021